PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Analyze analyst forecasts for the company and compare them with competitors.
124.50M
Better than MCRB's estimated revenue of 0.
-24.90M
Worse than MCRB's estimated ebitda of 0.
0.56
Better than MCRB's estimated eps of -9.75.
16.74M
Better than MCRB's estimated net income of -1.52B.
-24.90M
Worse than MCRB's estimated ebit of 0.
4.61B
Worse than MCRB's estimated sg&a expense of 0.
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.
Analyze DCF forecasts for the company and compare them with competitors.
No Data
No DCF data available for this metric in the selected year.
-50.53%
Worse than MCRB's revenue growth rate of 1.23%.
No Data
No DCF data available for this metric in the selected year.
-20.00%
Better than MCRB's ebitda margin of -42.76%.
No Data
No DCF data available for this metric in the selected year.
-20.00%
Better than MCRB's ebit margin of -45.02%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
100.00%
Equal to MCRB's cash as percentage of revenue of 100.00%.
No Data
No DCF data available for this metric in the selected year.
40.00%
Worse than MCRB's receivables as percentage of revenue of 27.03%.
No Data
No DCF data available for this metric in the selected year.
40.00%
Worse than MCRB's inventories as percentage of revenue of 24.69%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Worse than MCRB's payables as percentage of revenue of 44.89%.
No Data
No DCF data available for this metric in the selected year.
-29.43%
Better than MCRB's capex as percentage of revenue of -22.94%.
4.99%
Better than MCRB's weighted average cost of capital (wacc) of 16.73%.
5.02%
Better than MCRB's cost of equity of 17.67%.
4.08%
Worse than MCRB's cost of debt of 4.07%.
-0.23
Better than MCRB's beta of 2.88.
30.07M
Better than MCRB's diluted shares outstanding of 155.40M.
1.57M
Better than MCRB's total debt of 91.64M.
49.31M
Worse than MCRB's total equity of 1.24B.
50.89M
Worse than MCRB's total capital of 1.33B.
3.09%
Better than MCRB's debt weighting of 6.88%.
96.91%
Better than MCRB's equity weighting of 93.12%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
2.00%
Equal to MCRB's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Better than MCRB's net debt of 60.85M.
71.33M
Better than MCRB's equity value of -60.27M.
2.37
Better than MCRB's equity value per share of -0.39.